STOCK TITAN

[8-K] Envoy Medical, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

OCI N.V. and its Dutch subsidiaries OCI Intermediate B.V. and OCI Chemicals B.V. have filed a Schedule 13G disclosing a sizeable passive stake in Methanex Corporation (NASDAQ/TSX: MEOH). The filing, triggered by a June 27 2025 event date, shows beneficial ownership of 9,944,308 common shares, equal to 12.9 % of Methanex’s 77,339,520 shares outstanding as of June 30 2025.

All shares are held with shared voting power over 7,726,218 shares – subject to an undertaking not to vote more than 9.99 % of the company’s outstanding stock until Toronto Stock Exchange listing conditions are satisfied – and shared dispositive power over the full 9.94 million-share position. The reporting persons possess no sole voting or dispositive authority, underscoring the filing’s passive intent. Each entity certifies that the securities were not acquired for the purpose of influencing control, in line with Schedule 13G requirements.

The disclosure makes OCI – a Netherlands-based global producer of nitrogen, methanol and hydrogen products – one of Methanex’s largest known shareholders. While the filing does not announce any transaction terms or strategic plans, the scale of the stake (worth roughly US$450-500 million at recent prices) signals institutional confidence in Methanex’s methanol market outlook and could foreshadow future collaboration or corporate activity within the global methanol value chain.

OCI N.V. e le sue controllate olandesi OCI Intermediate B.V. e OCI Chemicals B.V. hanno presentato un Schedule 13G, rivelando una significativa partecipazione passiva in Methanex Corporation (NASDAQ/TSX: MEOH). La comunicazione, relativa all’evento del 27 giugno 2025, indica una detenzione effettiva di 9.944.308 azioni ordinarie, pari al 12,9% delle 77.339.520 azioni in circolazione di Methanex al 30 giugno 2025.

Tutte le azioni sono detenute con potere di voto condiviso su 7.726.218 azioni – soggetto a un impegno a non votare oltre il 9,99% del capitale sociale fino al soddisfacimento delle condizioni di quotazione alla Borsa di Toronto – e con potere dispositive condiviso sull’intera posizione di 9,94 milioni di azioni. Le persone che hanno effettuato la comunicazione non detengono potere di voto o dispositive esclusivo, sottolineando la natura passiva della partecipazione. Ogni entità certifica che i titoli non sono stati acquisiti con l’intento di influenzare il controllo, in conformità con i requisiti dello Schedule 13G.

La comunicazione rende OCI – produttore globale olandese di prodotti a base di azoto, metanolo e idrogeno – uno dei maggiori azionisti noti di Methanex. Sebbene il documento non annunci termini di transazioni o piani strategici, l’entità della partecipazione (del valore approssimativo di 450-500 milioni di dollari USA ai prezzi recenti) indica una fiducia istituzionale nelle prospettive di mercato del metanolo di Methanex e potrebbe anticipare future collaborazioni o attività societarie nella catena globale del valore del metanolo.

OCI N.V. y sus filiales neerlandesas OCI Intermediate B.V. y OCI Chemicals B.V. han presentado un Schedule 13G revelando una participación pasiva significativa en Methanex Corporation (NASDAQ/TSX: MEOH). La presentación, motivada por un evento ocurrido el 27 de junio de 2025, muestra una propiedad beneficiosa de 9.944.308 acciones comunes, equivalentes al 12,9 % de las 77.339.520 acciones en circulación de Methanex al 30 de junio de 2025.

Todas las acciones están bajo poder de voto compartido sobre 7.726.218 acciones – sujeto a un compromiso de no votar más del 9,99 % del capital social hasta que se cumplan las condiciones de listado en la Bolsa de Toronto – y poder dispositivo compartido sobre la posición total de 9,94 millones de acciones. Las personas que reportan no poseen autoridad exclusiva de voto ni dispositiva, lo que subraya la intención pasiva de la presentación. Cada entidad certifica que los valores no fueron adquiridos con el propósito de influir en el control, conforme a los requisitos del Schedule 13G.

La divulgación convierte a OCI – un productor global con sede en los Países Bajos de productos de nitrógeno, metanol e hidrógeno – en uno de los mayores accionistas conocidos de Methanex. Aunque la presentación no anuncia términos de transacción ni planes estratégicos, la magnitud de la participación (valorada aproximadamente entre 450 y 500 millones de dólares estadounidenses según los precios recientes) indica confianza institucional en las perspectivas del mercado del metanol de Methanex y podría anticipar futuras colaboraciones o actividades corporativas dentro de la cadena global de valor del metanol.

OCI N.V.와 그 네덜란드 자회사인 OCI Intermediate B.V. 및 OCI Chemicals B.V.가 Methanex Corporation (NASDAQ/TSX: MEOH)에 대한 상당한 규모의 수동적 지분을 공개하는 Schedule 13G를 제출했습니다. 2025년 6월 27일 발생한 사건을 계기로 제출된 이 문서에는 2025년 6월 30일 기준 Methanex의 총 77,339,520주 중 9,944,308주(12.9%)에 대한 실질 소유권이 명시되어 있습니다.

모든 주식은 7,726,218주에 대한 공동 의결권으로 보유되고 있으며 – 토론토 증권거래소 상장 조건이 충족될 때까지 회사 발행 주식의 9.99% 이상 투표하지 않겠다는 약속이 포함되어 있습니다 – 그리고 총 9.94백만 주의 공동 처분권을 가지고 있습니다. 보고자는 단독 의결권이나 처분권을 보유하지 않으며, 이는 제출 문서가 수동적임을 강조합니다. 각 기관은 증권이 지배권에 영향을 미칠 목적으로 취득되지 않았음을 Schedule 13G 요건에 따라 증명합니다.

이번 공개로 네덜란드에 본사를 둔 질소, 메탄올, 수소 제품의 글로벌 생산업체인 OCI가 Methanex의 가장 큰 알려진 주주 중 하나가 되었습니다. 제출 문서에는 거래 조건이나 전략적 계획이 포함되어 있지 않지만, 최근 가격 기준 약 4억 5천만에서 5억 달러 상당의 지분 규모는 Methanex의 메탄올 시장 전망에 대한 기관의 신뢰를 나타내며, 향후 글로벌 메탄올 가치 사슬 내 협력이나 기업 활동의 신호일 수 있습니다.

OCI N.V. et ses filiales néerlandaises OCI Intermediate B.V. et OCI Chemicals B.V. ont déposé un Schedule 13G révélant une participation passive importante dans Methanex Corporation (NASDAQ/TSX : MEOH). Le dépôt, déclenché par un événement survenu le 27 juin 2025, montre une propriété bénéficiaire de 9 944 308 actions ordinaires, soit 12,9 % des 77 339 520 actions en circulation de Methanex au 30 juin 2025.

Toutes les actions sont détenues avec un pouvoir de vote partagé sur 7 726 218 actions – sous réserve d'un engagement à ne pas voter plus de 9,99 % des actions en circulation jusqu'à ce que les conditions de cotation à la Bourse de Toronto soient remplies – et un pouvoir discrétionnaire partagé sur la totalité de la position de 9,94 millions d’actions. Les personnes déclarantes ne disposent d’aucun pouvoir exclusif de vote ou de disposition, soulignant ainsi l’intention passive du dépôt. Chaque entité certifie que les titres n’ont pas été acquis dans le but d’influencer le contrôle, conformément aux exigences du Schedule 13G.

Cette divulgation fait d’OCI – un producteur mondial basé aux Pays-Bas de produits à base d’azote, de méthanol et d’hydrogène – l’un des plus grands actionnaires connus de Methanex. Bien que le dépôt n’annonce aucun terme de transaction ni plan stratégique, l’ampleur de la participation (d’une valeur d’environ 450 à 500 millions de dollars américains aux cours récents) témoigne de la confiance institutionnelle dans les perspectives du marché du méthanol de Methanex et pourrait présager de futures collaborations ou activités d’entreprise au sein de la chaîne de valeur mondiale du méthanol.

OCI N.V. und seine niederländischen Tochtergesellschaften OCI Intermediate B.V. und OCI Chemicals B.V. haben ein Schedule 13G eingereicht, das eine bedeutende passive Beteiligung an der Methanex Corporation (NASDAQ/TSX: MEOH) offenlegt. Die Meldung, ausgelöst durch ein Ereignis am 27. Juni 2025, zeigt eine wirtschaftliche Eigentümerschaft von 9.944.308 Stammaktien, was 12,9 % der 77.339.520 ausstehenden Aktien von Methanex zum 30. Juni 2025 entspricht.

Alle Aktien werden mit gemeinsamem Stimmrecht über 7.726.218 Aktien gehalten – unter der Auflage, nicht mehr als 9,99 % der ausstehenden Aktien bis zur Erfüllung der Notierungsbedingungen an der Toronto Stock Exchange zu stimmen – sowie mit gemeinsamem Verfügungsrecht über die gesamte Position von 9,94 Millionen Aktien. Die meldenden Personen besitzen keine alleinige Stimm- oder Verfügungsgewalt, was die passive Absicht der Meldung unterstreicht. Jede Einheit bestätigt, dass die Wertpapiere nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden, gemäß den Anforderungen des Schedule 13G.

Die Offenlegung macht OCI – einen globalen Produzenten von Stickstoff-, Methanol- und Wasserstoffprodukten mit Sitz in den Niederlanden – zu einem der größten bekannten Aktionäre von Methanex. Obwohl die Meldung keine Transaktionsbedingungen oder strategischen Pläne bekannt gibt, signalisiert das Ausmaß der Beteiligung (im Wert von etwa 450 bis 500 Millionen US-Dollar zu den jüngsten Kursen) institutionelles Vertrauen in die Methanolmarktprognosen von Methanex und könnte auf zukünftige Kooperationen oder Unternehmensaktivitäten innerhalb der globalen Methanol-Wertschöpfungskette hinweisen.

Positive
  • OCI acquires a 12.9 % economic interest, signaling institutional confidence in Methanex’s business and potentially strengthening the shareholder base.
  • Block ownership reduces free-float supply, which can offer near-term support to Methanex’s share price.
  • Strategic industry alignment between OCI and Methanex could open the door to collaborations or future corporate actions.
Negative
  • Potential overhang risk exists if OCI later decides to divest its sizable position, which could pressure the stock.
  • Voting power capped at 9.99 %, limiting any immediate governance influence while still raising questions about longer-term intentions.

Insights

TL;DR – OCI reveals a 12.9 % passive stake in Methanex, indicating strategic interest and potential industry alignment.

The 9.9 million-share position makes OCI one of Methanex’s largest shareholders, representing c. US$0.5 bn. Although filed on Schedule 13G (passive intent), OCI’s core business—methanol and hydrogen derivatives—closely overlaps Methanex’s. Large cross-industry stakes often precede joint ventures, board representation requests or, in the longer term, control transactions. Even without activism, the holding removes a sizeable free-float block and may support the share price. The voting cap to 9.99 % suggests OCI is complying with TSX rules while still maintaining economic exposure. Overall, the news is incrementally positive for sentiment and may fuel speculation about strategic options.

TL;DR – Filing is neutral from a governance perspective; stake is large but expressly passive.

Schedule 13G indicates OCI has no current intent to influence control, and the certification language reinforces that stance. The absence of sole voting rights and the self-imposed 9.99 % voting cap further limit governance impact. Methanex’s existing board and management retain full control. Investors should monitor future filings; a switch to Schedule 13D would mark a material shift. For now, governance risk is low, and the disclosure mainly enhances transparency.

OCI N.V. e le sue controllate olandesi OCI Intermediate B.V. e OCI Chemicals B.V. hanno presentato un Schedule 13G, rivelando una significativa partecipazione passiva in Methanex Corporation (NASDAQ/TSX: MEOH). La comunicazione, relativa all’evento del 27 giugno 2025, indica una detenzione effettiva di 9.944.308 azioni ordinarie, pari al 12,9% delle 77.339.520 azioni in circolazione di Methanex al 30 giugno 2025.

Tutte le azioni sono detenute con potere di voto condiviso su 7.726.218 azioni – soggetto a un impegno a non votare oltre il 9,99% del capitale sociale fino al soddisfacimento delle condizioni di quotazione alla Borsa di Toronto – e con potere dispositive condiviso sull’intera posizione di 9,94 milioni di azioni. Le persone che hanno effettuato la comunicazione non detengono potere di voto o dispositive esclusivo, sottolineando la natura passiva della partecipazione. Ogni entità certifica che i titoli non sono stati acquisiti con l’intento di influenzare il controllo, in conformità con i requisiti dello Schedule 13G.

La comunicazione rende OCI – produttore globale olandese di prodotti a base di azoto, metanolo e idrogeno – uno dei maggiori azionisti noti di Methanex. Sebbene il documento non annunci termini di transazioni o piani strategici, l’entità della partecipazione (del valore approssimativo di 450-500 milioni di dollari USA ai prezzi recenti) indica una fiducia istituzionale nelle prospettive di mercato del metanolo di Methanex e potrebbe anticipare future collaborazioni o attività societarie nella catena globale del valore del metanolo.

OCI N.V. y sus filiales neerlandesas OCI Intermediate B.V. y OCI Chemicals B.V. han presentado un Schedule 13G revelando una participación pasiva significativa en Methanex Corporation (NASDAQ/TSX: MEOH). La presentación, motivada por un evento ocurrido el 27 de junio de 2025, muestra una propiedad beneficiosa de 9.944.308 acciones comunes, equivalentes al 12,9 % de las 77.339.520 acciones en circulación de Methanex al 30 de junio de 2025.

Todas las acciones están bajo poder de voto compartido sobre 7.726.218 acciones – sujeto a un compromiso de no votar más del 9,99 % del capital social hasta que se cumplan las condiciones de listado en la Bolsa de Toronto – y poder dispositivo compartido sobre la posición total de 9,94 millones de acciones. Las personas que reportan no poseen autoridad exclusiva de voto ni dispositiva, lo que subraya la intención pasiva de la presentación. Cada entidad certifica que los valores no fueron adquiridos con el propósito de influir en el control, conforme a los requisitos del Schedule 13G.

La divulgación convierte a OCI – un productor global con sede en los Países Bajos de productos de nitrógeno, metanol e hidrógeno – en uno de los mayores accionistas conocidos de Methanex. Aunque la presentación no anuncia términos de transacción ni planes estratégicos, la magnitud de la participación (valorada aproximadamente entre 450 y 500 millones de dólares estadounidenses según los precios recientes) indica confianza institucional en las perspectivas del mercado del metanol de Methanex y podría anticipar futuras colaboraciones o actividades corporativas dentro de la cadena global de valor del metanol.

OCI N.V.와 그 네덜란드 자회사인 OCI Intermediate B.V. 및 OCI Chemicals B.V.가 Methanex Corporation (NASDAQ/TSX: MEOH)에 대한 상당한 규모의 수동적 지분을 공개하는 Schedule 13G를 제출했습니다. 2025년 6월 27일 발생한 사건을 계기로 제출된 이 문서에는 2025년 6월 30일 기준 Methanex의 총 77,339,520주 중 9,944,308주(12.9%)에 대한 실질 소유권이 명시되어 있습니다.

모든 주식은 7,726,218주에 대한 공동 의결권으로 보유되고 있으며 – 토론토 증권거래소 상장 조건이 충족될 때까지 회사 발행 주식의 9.99% 이상 투표하지 않겠다는 약속이 포함되어 있습니다 – 그리고 총 9.94백만 주의 공동 처분권을 가지고 있습니다. 보고자는 단독 의결권이나 처분권을 보유하지 않으며, 이는 제출 문서가 수동적임을 강조합니다. 각 기관은 증권이 지배권에 영향을 미칠 목적으로 취득되지 않았음을 Schedule 13G 요건에 따라 증명합니다.

이번 공개로 네덜란드에 본사를 둔 질소, 메탄올, 수소 제품의 글로벌 생산업체인 OCI가 Methanex의 가장 큰 알려진 주주 중 하나가 되었습니다. 제출 문서에는 거래 조건이나 전략적 계획이 포함되어 있지 않지만, 최근 가격 기준 약 4억 5천만에서 5억 달러 상당의 지분 규모는 Methanex의 메탄올 시장 전망에 대한 기관의 신뢰를 나타내며, 향후 글로벌 메탄올 가치 사슬 내 협력이나 기업 활동의 신호일 수 있습니다.

OCI N.V. et ses filiales néerlandaises OCI Intermediate B.V. et OCI Chemicals B.V. ont déposé un Schedule 13G révélant une participation passive importante dans Methanex Corporation (NASDAQ/TSX : MEOH). Le dépôt, déclenché par un événement survenu le 27 juin 2025, montre une propriété bénéficiaire de 9 944 308 actions ordinaires, soit 12,9 % des 77 339 520 actions en circulation de Methanex au 30 juin 2025.

Toutes les actions sont détenues avec un pouvoir de vote partagé sur 7 726 218 actions – sous réserve d'un engagement à ne pas voter plus de 9,99 % des actions en circulation jusqu'à ce que les conditions de cotation à la Bourse de Toronto soient remplies – et un pouvoir discrétionnaire partagé sur la totalité de la position de 9,94 millions d’actions. Les personnes déclarantes ne disposent d’aucun pouvoir exclusif de vote ou de disposition, soulignant ainsi l’intention passive du dépôt. Chaque entité certifie que les titres n’ont pas été acquis dans le but d’influencer le contrôle, conformément aux exigences du Schedule 13G.

Cette divulgation fait d’OCI – un producteur mondial basé aux Pays-Bas de produits à base d’azote, de méthanol et d’hydrogène – l’un des plus grands actionnaires connus de Methanex. Bien que le dépôt n’annonce aucun terme de transaction ni plan stratégique, l’ampleur de la participation (d’une valeur d’environ 450 à 500 millions de dollars américains aux cours récents) témoigne de la confiance institutionnelle dans les perspectives du marché du méthanol de Methanex et pourrait présager de futures collaborations ou activités d’entreprise au sein de la chaîne de valeur mondiale du méthanol.

OCI N.V. und seine niederländischen Tochtergesellschaften OCI Intermediate B.V. und OCI Chemicals B.V. haben ein Schedule 13G eingereicht, das eine bedeutende passive Beteiligung an der Methanex Corporation (NASDAQ/TSX: MEOH) offenlegt. Die Meldung, ausgelöst durch ein Ereignis am 27. Juni 2025, zeigt eine wirtschaftliche Eigentümerschaft von 9.944.308 Stammaktien, was 12,9 % der 77.339.520 ausstehenden Aktien von Methanex zum 30. Juni 2025 entspricht.

Alle Aktien werden mit gemeinsamem Stimmrecht über 7.726.218 Aktien gehalten – unter der Auflage, nicht mehr als 9,99 % der ausstehenden Aktien bis zur Erfüllung der Notierungsbedingungen an der Toronto Stock Exchange zu stimmen – sowie mit gemeinsamem Verfügungsrecht über die gesamte Position von 9,94 Millionen Aktien. Die meldenden Personen besitzen keine alleinige Stimm- oder Verfügungsgewalt, was die passive Absicht der Meldung unterstreicht. Jede Einheit bestätigt, dass die Wertpapiere nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden, gemäß den Anforderungen des Schedule 13G.

Die Offenlegung macht OCI – einen globalen Produzenten von Stickstoff-, Methanol- und Wasserstoffprodukten mit Sitz in den Niederlanden – zu einem der größten bekannten Aktionäre von Methanex. Obwohl die Meldung keine Transaktionsbedingungen oder strategischen Pläne bekannt gibt, signalisiert das Ausmaß der Beteiligung (im Wert von etwa 450 bis 500 Millionen US-Dollar zu den jüngsten Kursen) institutionelles Vertrauen in die Methanolmarktprognosen von Methanex und könnte auf zukünftige Kooperationen oder Unternehmensaktivitäten innerhalb der globalen Methanol-Wertschöpfungskette hinweisen.

false 0001840877 0001840877 2025-06-26 2025-06-26 0001840877 COCH:ClassacommonStockParValue0.0001PerShareMember 2025-06-26 2025-06-26 0001840877 COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassaCommonStockAtExercisePriceOf11.50PerShareMember 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 26, 2025

 

 

 

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40133   86-1369123
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

4875 White Bear Parkway
White Bear Lake, MN
  55110
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (877) 900-3277

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share   COCH   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   COCHW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01: Entry Into a Material Definitive Agreement

 

On June 26, 2025, Envoy Medical, Inc. (the “Company”) drew the remaining $5,000,000 of available principal under the promissory note, dated as of March 6, 2025 (the “Note”), between the Company and GAT Funding, LLC (“GAT”). GAT is an entity controlled by Glen Taylor, who is a member of the Company’s board of directors and the controlling stockholder of the Company.

 

As a commitment fee for the additional draw and pursuant to the terms of the Note, the Company issued GAT a warrant to purchase 750,000 shares of its Class A Common at an exercise price of $1.48 (the “Warrant”), which was the closing trading price of the Class A Common Stock on the date of the draw. The Warrant has a two year exercise period.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Note is incorporated by reference into this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Warrant is incorporated by reference into this Item 3.02. The issuance of shares of the Company’s Class A Common Stock underlying the Warrants will be made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D thereunder.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number
  Description
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENVOY MEDICAL, INC.
   
July 2, 2025 By: /s/ Brent T. Lucas
    Brent T. Lucas
    Chief Executive Officer

 

 

2

 

 

FAQ

How many Methanex (MEOH) shares does OCI now own?

OCI and its subsidiaries report beneficial ownership of 9,944,308 common shares.

What percentage of Methanex’s outstanding stock does the OCI stake represent?

The filing states the stake equals 12.9 % of the 77,339,520 shares outstanding as of June 30 2025.

Does OCI have full voting control over its Methanex shares?

No. OCI reports shared voting power on 7,726,218 shares and has agreed not to vote more than 9.99 % of the total outstanding shares.

Is OCI seeking to take control of Methanex?

The Schedule 13G certification affirms the stake is passive; OCI states it did not acquire the shares to influence control.

When was the ownership threshold that triggered this Schedule 13G crossed?

The event date requiring the filing is June 27 2025.

Could OCI’s investment lead to future strategic actions?

While the filing is passive, the industry overlap means investors should watch for any future Schedule 13D or partnership announcements.
Envoy Medical

NASDAQ:COCH

COCH Rankings

COCH Latest News

COCH Latest SEC Filings

COCH Stock Data

31.56M
10.08M
50.22%
9.05%
0.49%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WHITE BEAR LAKE